Gilead is writing off its anti-BCMA CAR-T for multiple myeloma, eliminating one of the many efforts focused on that target and driving a big part of the company’s $820 million impairment charge for R&D in the 4th quarter of last year.  But this could just be a taste of what’s to come. A spokesperson sent … Continue reading Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?